Alsop K, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30:2654-2663

Antoniou A, et al. Am J Hum Genet. 2003; 72(5):1117-1130.

Banez LL et al. (2007). Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA. 298(19):2275–2280.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68(6):394–424.

Cirino AL, Ho CY. Genetic testing for inherited heart disease. Circulation. 2013;128(1):e4-e8. doi:10.1161/CIRCULATIONAHA.113.002252

Draisma G et al. (2009) Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 101(6):374–383.

Easton DF, et al. Am J Hum Genet. 1995;56(1):265-271

Ford D, et al. Lancet. 1994;343(8899):692-695.

Genetic testing fact sheet. (n.d.). Available at

National Cancer Institute. BRCA 1 and BRCA 2: Cancer Risk and Genetic testing. Available at

Ovarian Cancer National Alliance. Treatment. Available at

Prostate cancer treatment (pdq®)–health professional version. (n.d.). Available at

Prostate cancer: MedlinePlus Genetics. (2020, August 18). Available at

Rawla P (2019). Epidemiology of Prostate Cancer. World J Oncol. 10(2): 63–8.

Serefoglu EC et al. (2013). How reliable is 12-core prostate biopsy procedure in the detection of prostate cancer? Can Urol Assoc J. May-Jun; 7(5-6)

Struewing JP, et al. N Engl J Med. 1997;336(20):1401-1408

U.S. Food and Drug Administration. Personalized medicine and companion diagnostics go hand-in-hand. Available at